Wuxi-developed cancer drug reaches US market

The breakthrough is part of a broader trend. Wuxi is seeing more local drugmakers expand overseas through different strategies.

D3 Bio is advancing four drug candidates through global clinical trials, while Abogen Biosciences signed a licensing agreement with Swiss pharmaceutical giant Novartis in October, with a potential deal value reaching $7.78 billion.

Meanwhile, Norroy Bioscience is pursuing international opportunities in radiopharmaceuticals, with its candidate NYM096 receiving FDA Breakthrough Therapy and Fast Track designations. The company has also exported radiopharmaceutical manufacturing equipment to India.

Behind these advances is a growing ecosystem supporting global drug development. Wuxi has attracted international clinical laboratory service provider LabConnect and established a 2 billion yuan ($304.67 million) biomedical accelerator fund with Vivo Capital.

The city's biomedical industry now exceeds 200 billion yuan in scale, with nearly 2,500 companies and five domestically developed Category 1 innovative drugs approved for marketing.

From individual drug approvals to global partnerships and technology exports, Wuxi is building a diverse pipeline of pharmaceutical innovation with ambitions that extend well beyond China.